Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

The therapeutic potential of miR-486-5p in ischemic acute kidney injury

FY 2020-21

Summary
Acute kidney injury (AKI) is a condition where patients experience a rapid decline in kidney function. AKI is a common complication of hospitalization with a high prevalence in intensive care units and has a high mortality rate. Recovery from AKI has long-term consequences including an increased risk of death and new or progressive chronic kidney disease (CKD). In Canada, the annual cost attributed to AKI is estimated at approximately $200 million; more severe episodes of AKI are associated with incremental increases in hospital length of stay and cost (Collister D, et al. Clin J Am Soc Nephrol 2017). Despite these health and economic consequences, no effective intervention for AKI exists. One common cause of AKI is ischemia reperfusion injury, where the kidneys experience a period of reduced blood flow and lack of oxygen, followed by the return of blood supply. Damage to kidney endothelial cells further compromises blood supply throughout the kidneys, which can impair recovery and lead to chronic kidney disease (CKD). MicroRNAs (miRs) are small molecules that regulate the expression of proteins. The administration of microRNAs has been shown to protect against AKI in mice. Our lab has shown that the administration of miR-486-5p reduces ischemic AKI in mice. We will further characterize the mechanisms by which miR-486-5p protects against AKI, with a focus on endothelial function. We will increase our understanding of microRNA in human AKI by (i) studying the effects of miR-486-5p in ischemic AKI using a mouse model with chronic high blood pressure, which can affect susceptibility to AKI and CKD and (ii) conducting a systematic literature review of microRNA in human AKI. These studies will provide an important step towards the development of therapies for patients with AKI.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
440071
Name
Douvris Adrianna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The therapeutic potential of miR-486-5p in ischemic acute kidney injury
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Acute Kidney Injury; Angiogenesis; Animal Model Of Acute Kidney Injury; Apoptosis; Cell Culture; Endothelial Function; In Vitro Hypoxia Re-Oxygenation; Microrna; Quantitative Pcr For Rna Expression; Western Blot For Protein Expression
Abstract
Acute kidney injury (AKI) is a condition where patients experience a rapid decline in kidney function. AKI is a common complication of hospitalization with a high prevalence in intensive care units and has a high mortality rate. Recovery from AKI has long-term consequences including an increased risk of death and new or progressive chronic kidney disease (CKD). In Canada, the annual cost attributed to AKI is estimated at approximately $200 million; more severe episodes of AKI are associated with incremental increases in hospital length of stay and cost (Collister D, et al. Clin J Am Soc Nephrol 2017). Despite these health and economic consequences, no effective intervention for AKI exists. One common cause of AKI is ischemia reperfusion injury, where the kidneys experience a period of reduced blood flow and lack of oxygen, followed by the return of blood supply. Damage to kidney endothelial cells further compromises blood supply throughout the kidneys, which can impair recovery and lead to chronic kidney disease (CKD). MicroRNAs (miRs) are small molecules that regulate the expression of proteins. The administration of microRNAs has been shown to protect against AKI in mice. Our lab has shown that the administration of miR-486-5p reduces ischemic AKI in mice. We will further characterize the mechanisms by which miR-486-5p protects against AKI, with a focus on endothelial function. We will increase our understanding of microRNA in human AKI by (i) studying the effects of miR-486-5p in ischemic AKI using a mouse model with chronic high blood pressure, which can affect susceptibility to AKI and CKD and (ii) conducting a systematic literature review of microRNA in human AKI. These studies will provide an important step towards the development of therapies for patients with AKI.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Douvris, Adrianna
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
University of Ottawa - $105,000 Grant (2020-21) | Canada Spends